Beijing Biostar Pharmaceuticals Co (HKSE:02563) Notes Receivable: HK$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02563 Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
9 GF Score
Price HK$3.40
! 4 Warning Signs
View Full Analysis

What is Beijing Biostar Pharmaceuticals Co Notes Receivable?

Beijing Biostar Pharmaceuticals Co HKSE:02563 -4.23% 9 Notes Receivable is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review.

Beijing Biostar Pharmaceuticals Co's Notes Receivable for the quarter that ended in Dec. 2025 was HK$0.00 Mil.

Beijing Biostar Pharmaceuticals Co Notes Receivable Related Terms

Beijing Biostar Pharmaceuticals Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Beijing Biostar Pharmaceuticals Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Biostar Pharmaceuticals Co Notes Receivable Chart

Beijing Biostar Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Beijing Biostar Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
HKSE:02563
9GF Score
Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Biostar Pharmaceuticals Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0.00 Mil mean?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Notes Receivable of HK$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors.
Is Beijing Biostar Pharmaceuticals Co's Notes Receivable too high?
Beijing Biostar Pharmaceuticals Co's current Notes Receivable is HK$0.00 Mil. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Notes Receivable compare to VRTX and REGN?
Beijing Biostar Pharmaceuticals Co's Notes Receivable of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current Notes Receivable is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Notes Receivable of HK$0.00 Mil. The current Notes Receivable is HK$0.00 Mil. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Notes Receivable is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Biostar Pharmaceuticals Co Business Description

Address 22 Ronghua Middle Road, Suite 1202, Tower B, Yicheng Fortune Center, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score

Get the complete analysis for HKSE:02563

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.40
Price